FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to novel pyridyloxy derivatives or its pharmaceutically acceptable ester or a pharmaceutically acceptable salt of the mentioned derivatice or ester of general formula 
(I), wherein R represents a pyridyl group substituted by 1-3 groups independently specified in a group of substitutes A; the group of substitutes A represents a group comprising halogen atom, C1-C6 alkyl group and C1-C6 alkoxy group, and Me represents a methyl group. Also, the invention refers to specific compounds of formula (I), to a pharmaceutical composition and a receptor-γ activator/modulator on the basis of a compound of formula (I), to a method of treating and/or preventing a disease.
EFFECT: there are prepared novel pyridyloxy derivatives effective in treating the disease mediated by peroxisome proliferator activated receptor-γ (PPAR) γ.
37 cl, 2 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZIMIDAZOLE DERIVATIVES, BASED PHARMACEUTICAL COMPOSITION AND METHODS OF USING THEM | 2008 |
|
RU2456276C2 |
| BENZIMIDAZOLE DERIVATIVE | 2006 |
|
RU2409573C2 |
| CONDENSED HETEROCYCLIC COMPOUNDS | 2006 |
|
RU2408586C2 |
| MACROCYCLIC PYRIDAZINONE DERIVATIVES | 2014 |
|
RU2660435C2 |
| NEW 2-HETEROARYL-SUBSTITUTE BENZIMIDAZOLE DERIVATIVE | 2004 |
|
RU2329261C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2652117C2 |
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| USING EP4 RECEPTOR LIGANDS IN TREATMENT OF IL-6-MEDIATED DISEASES | 2003 |
|
RU2285527C2 |
| ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | 2011 |
|
RU2535671C1 |
| HETEROCYCLIC COMPOUNDS MODULATING ACTIVITY OF CHEMOKINE RECEPTOR, THEIR USING AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2001 |
|
RU2297413C2 |
